Related Experiment Video

Updated: Aug 15, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Atherogenesis and autoimmune disease: the model of lupus

I N Bruce1

  • 1The University of Manchester, Rheumatism Research Centre, Central Manchester and Manchester Children's University Hospitals Trust, Manchester, UK. ian.bruce@manchester.ac.uk

Lupus
|October 13, 2005
PubMed

Insights

Systemic lupus erythematosus (SLE) patients face accelerated atherosclerosis due to multifactorial causes beyond classic risks. Understanding the interplay of autoimmunity and atherogenesis is crucial for lupus and general atherosclerosis research.

Area of Science:

  • Cardiovascular Science
  • Rheumatology
  • Immunology

Background:

  • Accelerated atherosclerosis significantly increases morbidity and mortality in Systemic Lupus Erythematosus (SLE) patients.
  • While classic risk factors are implicated, they do not fully account for the elevated atherosclerosis risk in SLE.
  • Atherosclerosis is recognized as a chronic inflammatory condition, with SLE-specific factors like complement activation and immune complexes potentially driving atheroma development.

Purpose of the Study:

  • To explore the multifactorial etiology of accelerated atherosclerosis in SLE.
  • To highlight the role of autoimmune processes, autoantibodies (e.g., anticardiolipin antibodies), and therapeutic agents in SLE-related atherosclerosis.
  • To emphasize the need for a deeper understanding of the autoimmunity-atherogenesis interface in SLE.

Main Methods:

  • Review of existing literature on atherosclerosis risk factors in SLE.
  • Analysis of the role of immune system activation (complement, immune complexes, autoantibodies) in atherogenesis within the SLE context.
  • Evaluation of the differential effects of therapeutic agents, such as steroids and antimalarials, on atherosclerosis risk in SLE.

Main Results:

  • Classic risk factors partially explain atherosclerosis in SLE, but other factors contribute significantly.
  • Complement activation, immune complex formation, and autoantibodies (including anticardiolipin antibodies) are implicated in promoting atheroma.
  • Steroids exhibit a dual role, with low doses potentially anti-inflammatory and high doses exacerbating metabolic risk factors.
  • Antimalarials demonstrate beneficial effects, including lipid improvement, anti-inflammatory, and anti-platelet actions.

Conclusions:

  • The development of atherosclerosis in SLE is multifactorial, involving both traditional and autoimmune-driven pathways.
  • Understanding the complex interplay between autoimmunity and atherogenesis in SLE is vital for improving patient outcomes.
  • This research contributes to a broader understanding of atherosclerosis pathogenesis, potentially benefiting both lupus patients and the general population.

More Related Videos

Murine Bilateral Renal Lymphadenectomy06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...